Raymond M. Jordt - Jan 1, 2025 Form 4 Insider Report for Altimmune, Inc. (ALT)

Role
Chief Business Officer
Signature
/s/ Gregory Weaver, as Attorney-in-Fact
Stock symbol
ALT
Transactions as of
Jan 1, 2025
Transactions value $
-$17,917
Form type
4
Date filed
1/3/2025, 04:40 PM
Previous filing
Aug 1, 2024
Next filing
Jan 28, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALT Common Stock, par value $0.0001 Options Exercise $0 +9.38K +63.95% $0.00 24K Jan 1, 2025 Direct F1
transaction ALT Common Stock, par value $0.0001 Tax liability -$17.9K -2.49K -10.34% $7.21 21.6K Jan 1, 2025 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALT Restricted Stock Units Options Exercise $0 -9.38K -33.33% $0.00 18.8K Jan 1, 2025 Common Stock, par value $0.0001 9.38K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
F2 Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
F3 The RSUs become vested and released over four (4) years with 25% of the shares vesting on January 1, 2024, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.

Remarks:

Exhibit 24 - Power of Attorney